dc.contributor.author | Taprogge, J | |
dc.contributor.author | Vergara-Gil, A | |
dc.contributor.author | Leek, F | |
dc.contributor.author | Abreu, C | |
dc.contributor.author | Vávrová, L | |
dc.contributor.author | Carnegie-Peake, L | |
dc.contributor.author | Schumann, S | |
dc.contributor.author | Eberlein, U | |
dc.contributor.author | Lassmann, M | |
dc.contributor.author | Schurrat, T | |
dc.contributor.author | Luster, M | |
dc.contributor.author | Verburg, FA | |
dc.contributor.author | Vallot, D | |
dc.contributor.author | Vija, L | |
dc.contributor.author | Courbon, F | |
dc.contributor.author | Newbold, K | |
dc.contributor.author | Bardiès, M | |
dc.contributor.author | Flux, G | |
dc.date.accessioned | 2023-06-07T15:15:31Z | |
dc.date.available | 2023-06-07T15:15:31Z | |
dc.date.issued | 2023-09-01 | |
dc.identifier.citation | European Journal of Nuclear Medicine and Molecular Imaging, | |
dc.identifier.issn | 0340-6997 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5837 | |
dc.description.abstract | PURPOSE: Dosimetry is rarely performed for the treatment of differentiated thyroid cancer patients with Na[131I]I (radioiodine), and information regarding absorbed doses delivered is limited. Collection of dosimetry data in a multi-centre setting requires standardised quantitative imaging and dosimetry. A multi-national, multi-centre clinical study was performed to assess absorbed doses delivered to normal organs for differentiated thyroid cancer patients treated with Na[131I]I. METHODS: Patients were enrolled in four centres and administered fixed activities of 1.1 or 3.7 GBq of Na[131I]I using rhTSH stimulation or under thyroid hormone withdrawal according to local protocols. Patients were imaged using SPECT(/CT) at variable imaging time-points following standardised acquisition and reconstruction protocols. Whole-body retention data were collected. Dosimetry for normal organs was performed at two dosimetry centres and results collated. RESULTS: One hundred and five patients were recruited. Median absorbed doses per unit administered activity of 0.44, 0.14, 0.05 and 0.16 mGy/MBq were determined for the salivary glands of patients treated at centre 1, 2, 3 and 4, respectively. Median whole-body absorbed doses for 1.1 and 3.7 GBq were 0.05 Gy and 0.16 Gy, respectively. Median whole-body absorbed doses per unit administered activity of 0.04, 0.05, 0.04 and 0.04 mGy/MBq were calculated for centre 1, 2, 3 and 4, respectively. CONCLUSIONS: A wide range of normal organ doses were observed for differentiated thyroid cancer patients treated with Na[131I]I, highlighting the necessity for individualised dosimetry. The results show that data may be collated from multiple centres if minimum standards for the acquisition and dosimetry protocols can be achieved. | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.relation.ispartof | European Journal of Nuclear Medicine and Molecular Imaging | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-06-01 | |
dc.date.updated | 2023-06-07T14:00:03Z | |
rioxxterms.version | AM | |
rioxxterms.type | Journal Article/Review | |
pubs.organisational-group | /ICR | |
pubs.publication-status | Accepted | |
dc.contributor.icrauthor | Taprogge, Jan | |
icr.provenance | Deposited by Dr Jan Taprogge on 2023-06-07. Deposit type is initial. No. of files: 1. Files: MEDIRAD-dosimetry-paper_Resub1_ICR.pdf | |